What does issuance of warrants to purchase common stock mean?

Represents the accounting adjustments made to additional paid-in capital resulting from the issuance of warrants to purchase common stock. This reflects the non-cash equity impact of granting derivative instruments to investors or service providers as part of financing or compensation arrangements.

Evommune EVMN Issuance of warrants to purchase common stock

Issuance of warrants to purchase common stock at other companies

Oruka Therapeutics, Inc.ORKA

$2.52M-75.7%

ADMA BiologicsADMA

$1.4M—

Evommune EVMN

$150—

NovaGold ResourcesNG

$9.9M—

GigaCloud TechnologyGCT

$187K0.0%

Taysha Gene Therapies, Inc.TSHA

$409.25K—

Other financials

Income statement

See full

Revenue$1.6M+3.5%

Gross profit$961.1K+10.9%

Operating income-$682.8K-2,027%

Net income-$7.0M-5,414%

EPS (diluted)-$0.36-1,700%

Balance sheet

See full

Cash & equivalents$1.1M+401%

Total debt$2.0M—

Total equity-$4.5M-3,048%

Total assets$7.2M—

Cash flow

See full

Operating cash flow-$424.6K-341%

CapEx$1.0-99.8%

Free cash flow-$2.7M-4,996%

Valuation

See full

Market cap$848.59M+39.5%

Enterprise value$849.52M—

P/S127.3×—

Profitability

See full

Gross margin53.7%—

Operating margin-30.7%—

Net margin-90.1%—

Returns & leverage

See full

Return on equity275.7%—

Debt / equity1.4×—

Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued.

The official record: Evommune ’s 10-K, filed March 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's issuance of warrants to purchase common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Evommune 's issuance of warrants to purchase common stock?: Evommune (EVMN) reported issuance of warrants to purchase common stock of $150 in Q4 2025.
What does issuance of warrants to purchase common stock mean?: Represents the accounting adjustments made to additional paid-in capital resulting from the issuance of warrants to purchase common stock. This reflects the non-cash equity impact of granting derivative instruments to investors or service providers as part of financing or compensation arrangements.